Aquestive Therapeutics, Inc. (AQST) - Q1 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2025. Aquestive Therapeutics, Inc. is a pharmaceutical company developing medicines using innovative delivery technologies, primarily focusing on the Anaphylm (epinephrine) and Libervant (diazepam) product lines. The company operates as a single segment, serving as the exclusive manufacturer for its licensed products and advancing its proprietary pipeline. As of March 31, 2025, the company had 99.3 million shares of common stock outstanding.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $8,720 | $12,053 |
| Net Loss | $(22,930) | $(12,828) |
| Loss Per Share (Basic & Diluted) | $(0.24) | $(0.17) |
| Cash and Cash Equivalents | $68,657 | $95,200 |
| Net Cash Used in Operating Activities | $(23,400) | $(10,384) |
| Total Debt (Notes Payable, net) | $33,746 | $32,500 |
| Royalty Obligations (net) | $21,559 | $20,129 |
Revenue Composition (Q1 2025): Manufacture and supply ($7,193), License and royalty ($790), Co-development and research fees ($418), and Proprietary product revenue ($319).
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 28% ($3.3 million) year-over-year. This was driven primarily by a 32% drop in manufacture and supply revenue (largely due to a $4.5 million decrease in Suboxone revenues) and a 30% decline in license and royalty revenue.
- Expense Surge: Selling, General, and Administrative (SG&A) expenses increased 78% ($8.4 million) to $19.1 million. This spike was attributed to the Anaphylm PDUFA fee (~$4.3 million), higher legal fees ($2.25 million), and increased commercial spending (~$2.1 million).
- Net Loss Expansion: Net loss widened by 79% to $22.9 million, reflecting the revenue decline and significant increase in SG&A costs.
- Liquidity Position: Cash balances decreased by $2.9 million during the quarter. The company utilized its At-The-Market (ATM) facility to raise approximately $21.4 million in net proceeds during Q1 2025.
Guidance, Outlook, and Material Risks
- Libervant Regulatory Setback: On February 14, 2025, a U.S. District Court ruled in favor of Neurelis, vacating the FDA's approval of Libervant for patients aged 2-5. Consequently, the FDA converted the approval to "tentative," and Aquestive has ceased marketing activities for Libervant in the U.S. pending the outcome of an appeal. The company is seeking a determination of clinical superiority to overcome orphan drug exclusivity.
- Anaphylm Progress: The company completed its NDA submission to the FDA in Q1 2025. Positive topline data from a pediatric study was reported in April 2025. The company plans a product launch in Q1 2026, contingent on FDA acceptance of the NDA in Q2 2025.
- Liquidity Outlook: Management states that existing cash, expense management, and access to equity markets (ATM facility) provide liquidity for at least the next 12 months. However, the company expects to continue incurring significant operating losses.
- Debt Obligations: The company holds $45 million in 13.5% Senior Secured Notes due 2028. Principal amortization payments are scheduled to begin in June 2026.
- Legal Proceedings: The company is involved in Suboxone product liability litigation (MDL) regarding dental injuries, where Indivior has agreed to defend the company. The Neurelis litigation regarding Libervant remains a critical uncertainty.
Key Facts for Investor Verification
- Libervant Market Access: Verify the status of the appeal regarding the vacated FDA approval for Libervant and the timeline for potential reinstatement or alternative approval pathways.
- Anaphylm NDA Acceptance: Monitor for FDA acceptance of the NDA submission in Q2 2025, which is a prerequisite for the planned Q1 2026 launch.
- Cash Burn Rate: Assess the sustainability of the current cash burn (~$23 million per quarter) against the $68.7 million cash balance and the remaining $78 million capacity in the ATM facility.
- Suboxone Revenue Trend: Confirm the trajectory of Suboxone revenue, which remains a primary revenue driver but is facing generic competition and market share erosion.
- Debt Service Capability: Evaluate the company's ability to meet principal repayment obligations on the 13.5% Notes starting in June 2026 without further dilutive equity raises.